The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Open accessAbstract
BACKGROUND: The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. We hypothesized that such mutations would be detectable in the blood of some persons who are not known to have hematologic disorders. METHODS: We analyzed whole-exome sequencing data from DNA in the peripheral-blood cells of 17,182 persons who were unselected for hematologic phenotypes. We looked for somatic mutations by identifying previously characterized single-nucleotide variants and small insertions or deletions in 160 genes that are recurrently mutated in hematologic cancers. The presence of mutations was analyzed for an association with hematologic phenotypes, survival, and cardiovascular events. RESULTS: Detectable somatic mutations were rare in persons younger than 40 years of age but rose appreciably in frequency with age. Among persons 70 to 79 years of age, 80 to 89 years of age, and 90 to 108 years of age, these clonal mutations were observed in 9.5% (219 of 2300 persons), 11.7% (37 of 317), and 18.4% (19 of 103), respectively. The majority of the variants occurred in three genes: DNMT3A, TET2, and ASXL1. The presence of a somatic mutation was associated with an increase in the risk of hematologic cancer (hazard ratio, 11.1; 95% confidence interval [CI], 3.9 to 32.6), an increase in all-cause mortality (hazard ratio, 1.4; 95% CI, 1.1 to 1.8), and increases in the risks of incident coronary heart disease (hazard ratio, 2.0; 95% CI, 1.2 to 3.4) and ischemic stroke (hazard ratio, 2.6; 95% CI, 1.4 to 4.8). CONCLUSIONS: Age-related clonal hematopoiesis is a common condition that is associated with increases in the risk of hematologic cancer and in all-cause mortality, with the latter possibly due to an increased risk of cardiovascular disease. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Mutations in DNMT3A and TET2 account for over 90% of CH cases2,6”
From TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via CNS infiltration and enhanced phagocytosis in mice (2025) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP has emerged as a clinically relevant state associated with increased all-cause mortality and a broad spectrum of non-malignant diseases, most prominently atherosclerotic cardiovascular disease and stroke [1,4,5].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, progression to hematological malignancies depends on the type and complexity of mutations in CHIP.2,5,6”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More important, advanced age is the best predictor of CHIP, with a 5.6% or 18.4% prevalence in the sixth or ninth decade of life, respectively.2”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“are predicted to have high expansion rates (10% increase in mean VAF per year1, 2, 3,7)”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clone size, which is approximated by the variant allele fraction (VAF), has previously been shown to be an important predictor of risk for blood cancer1,17 and cardiovascular outcomes8,9.”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Despite its hematologically silent nature, CH has been associated with increased mortality and morbidity [1,32].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“although increased red cell distribution width (RDW) has been reported (Jaiswal et al., 2014).”
From Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling (2021) · cites this paper as Jaiswal et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Instead, the discovery of widespread clonal expansions in ageing human tissues19,50–52 raises the possibility that some somatic mutations contribute to ageing by driving clonal expansions of functionally altered cells at a cost to the organism49,53,54.”
From Somatic mutation rates scale with lifespan across mammals (2022) · cites this paper as [50]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Methods adhered to published guidelines 77 .”
From Clonal hematopoiesis-associated motoric deficits caused by monocyte-derived microglia accumulating in aging mice (2025) · cites this paper as [77]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The isolated effects of individual inflammatory cytokines, including type 1 interferons (IFNa/b) 1-3 , type 2 IFN (IFNg) 4-6 , TNFa 7,8 , and IL-1 9-11 , have been well-documented in mouse hematopoietic development.”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Interestingly, while IFNa alters mouse HSC marker Sca-1 2 (rendering difficult the quantification of progenitor cell frequency changes by flow cytometric assessment in mice), IFNa did not alter CD90 expression after treatment in the HSPCs ( Fig. 2e, Supplementary Fig. 3c ).”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previously, induction of IFNa in mice have yielded mixed results demonstrating either an upregulation 2 or downregulation 53 of TNFa.”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“clonal hematopoiesis is a frequent event in elderly people.”
From Aging of hematopoietic stem cells (2018) · cites this paper as [76]
In the citing paper
“Epigenetic genes that are relatively frequently affected in these conditions include DNMT3A, EZH2, TET2, and SETDB1.”
From Aging of hematopoietic stem cells (2018) · cites this paper as [76]
In the citing paper
“The phenomenon also appears to be counterintuitively well tolerated, where HSCs containing oncogenic mutations can overtake most of the hematopoietic system without transforming into leukemia (Jaiswal et al., 2014).”
From Unraveling Hematopoiesis through the Lens of Genomics (2020) · cites this paper as Jaiswal et al., 2014
In the citing paper
“The size of these mutant clones was massive; in one study, a median of ~18% of blood cells carried the mutations 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“For example, CHIP has been reported to be more common in older men 28 and smokers 27 and less common in Hispanics 28, although these associations are all relatively modest.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Indeed, in population-based cohorts that underwent exome sequencing, the presence of CHIP was associated with ~10-fold increased relative risk of these malignancies over several years of follow-up 27,28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“CHIP itself does not denote a malignancy, nor is it associated with clinically significant alterations in blood counts 28,63.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“In an initial study, this risk could not be explained by cancer deaths but was instead related to increased cardiovascular mortality 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“In one study, 4% of CHIP carriers developed a blood cancer over the subsequent 8 years, corresponding to ~0.5% of CHIP cases converting to malignancy per year 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Several studies have found that CHIP is associated with a 30–40% increased mortality risk 27,28,37.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Myeloid malignancies were most common, although some people with CHIP did develop lymphoid cancers 27,28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Indeed, some individuals with clonal hematopoiesis have virtually all of their blood cells arising from a single mutated HSC 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“CHIP has been found to be associated with a 30% increase in the likelihood of having type 2 diabetes (T2D) 28.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Studies of serial samples have shown that the trajectory of a clone can vary between people.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“Some people have clones that remain stagnant in size for many years, whereas other people have clones that show steady growth 28,33.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [28]
In the citing paper
“These findings are supported by recent findings demonstrating a causal link between mutations in HSPCs in the context of clonal hematopoiesis with indeterminate origin and altered transcriptional output of macrophages, which affect the vascular wall and contributes to atherosclerosis.83,84”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
Self-citationInflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,796
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationMacrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Flagged first, then by citations
1 of the 48 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 1,023
Molecular tumour boards — current and future considerations for precision oncology
Tsimberidou, A. M., Kahle, M., Vo, H. H., Baysal, M. A., Johnson, A. M., & Meric‐Bernstam, F. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00824-4 · Cited by 145
Challenges and advances in the management of inflammation in atherosclerosis
Xing, Y., & Lin, X. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.06.016 · Cited by 147
Mochizuki‐Kashio, M., Aoyama, K., Sashida, G., Oshima, M., Tomioka, T., Muto, T., Wang, C., & Iwama, A. (2015) · Blood · doi:10.1182/blood-2015-03-634428 · Cited by 147
Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient
Plana, J. C., Thavendiranathan, P., Bucciarelli‐Ducci, C., & Lancellotti, P. (2018) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2018.06.003 · Cited by 145
Valent, P., Orazi, A., Savona, M. R., Patnaik, M. M., Onida, F., van de Loosdrecht, A. A., Haase, D. T., Haferlach, T., Elena, C., Pleyer, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.222059 · Cited by 141
Abplanalp, W. T., Mas‐Peiró, S., Cremer, S., John, D., Dimmeler, S., & Zeiher, A. M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2468 · Cited by 147
Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis
Saiki, R., Momozawa, Y., Nannya, Y., Nakagawa, M. M., Ochi, Y., Yoshizato, T., Terao, C., Kuroda, Y., Shiraishi, Y., Chiba, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01411-9 · Cited by 143
Clonal hematopoiesis is associated with risk of severe Covid-19
Bolton, K. L., Koh, Y., Foote, M. B., Im, H., Jee, J., Sun, C.-H., Safonov, A. M., Ptashkin, R. N., Moon, J. H., Lee, J. Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26138-6 · Cited by 148
Nam, A. S., Dusaj, N., Izzo, F., Murali, R., Myers, R. M., Mouhieddine, T. H., Sotelo, J., Benbarche, S., Waarts, M., Gaiti, F., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01179-9 · Cited by 140
Ness, K. K., Kirkland, J. L., Gramatges, M. M., Wang, Z., Kundu, M., McCastlain, K., Li-Harms, X., Zhang, J., Tchkonia, T., Pluijm, S. M. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7467 · Cited by 143
Christen, F., Hoyer, K., Yoshida, K., Hou, H., Waldhüter, N., Heuser, M., Hills, R. K., Chan, W., Hablesreiter, R., Blau, O., et al. (2019) · Blood · doi:10.1182/blood-2018-05-852822 · Cited by 144
Inflammasomes, neutrophil extracellular traps, and cholesterol
Tall, A. R., & Westerterp, M. (2019) · Journal of Lipid Research · doi:10.1194/jlr.s091280 · Cited by 141
Slavin, T. P., Maxwell, K. N., Lilyquist, J., Vijai, J., Neuhausen, S. L., Hart, S. N., Ravichandran, V., Thomas, T., Maria, A., Villano, D., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0024-8 · Cited by 143
DNA methylation as a transcriptional regulator of the immune system
Morales‐Nebreda, L., McLafferty, F. S., & Singer, B. D. (2018) · Translational research · doi:10.1016/j.trsl.2018.08.001 · Cited by 141
Chae, Y. K., & Oh, M. S. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.022 · Cited by 142
Rolfo, C. D., Cardona, A. F., Cristofanilli, M., Paz-Ares, L. G., Díaz‐Mochon, J. J., Durán, I., Raez, L. E., Russo, A., Lorente, J. A., Malapelle, U., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102978 · Cited by 143
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
Sen, T., Takahashi, N., Chakraborty, S., Takebe, N., Nassar, A. H., Karim, N. A., Puri, S., & Naqash, A. R. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00914-x · Cited by 143
Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations
Castro-Giner, F., Gkountela, S., Donato, C., Alborelli, I., Quagliata, L., Ng, C. K. Y., Piscuoglio, S., & Aceto, N. (2018) · Diagnostics · doi:10.3390/diagnostics8020031 · Cited by 142
The genomic landscapes of individual melanocytes from human skin
Tang, J., Fewings, E., Chang, D., Zeng, H., Liu, S., Jorapur, A., Belote, R. L., McNeal, A. S., Tan, T. M., Yeh, I., et al. (2020) · Nature · doi:10.1038/s41586-020-2785-8 · Cited by 142
A comprehensive transcriptome signature of murine hematopoietic stem cell aging
Flohr Svendsen, A., Yang, D., Kim, K., Lazare, S., Skinder, N., Zwart, E., Mura-Meszaros, A., Ausema, A., von Eyss, B., de Haan, G., et al. (2021) · Blood · doi:10.1182/blood.2020009729 · Cited by 138
Zhang, C. R. C., Nix, D., Gregory, M., Ciorba, M. A., Ostrander, E. L., Newberry, R. D., Spencer, D. H., & Challen, G. A. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.11.008 · Cited by 137
“Despite the overall prevalence of CHIP, few of these individuals progress to hematopoietic malignancy [1, 2, 5, 7, 8].”
BackgroundAge-related mutations and chronic myelomonocytic leukemia
Mason, C. C., Khorashad, J. S., Tantravahi, S. K., Kelley, T. W., Zabriskie, M. S., Yan, D., Pomicter, A. D., Reynolds, K. R., Eiring, A. M., Kronenberg, Z. N., et al. (2015) · Leukemia · doi:10.1038/leu.2015.337 · Cited by 138
The role of ASXL1 in hematopoiesis and myeloid malignancies
Asada, S., Fujino, T., Goyama, S., & Kitamura, T. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03084-7 · Cited by 142
The molecular genetics of sideroblastic anemia
Ducamp, S., & Fleming, M. D. (2019) · Blood · doi:10.1182/blood-2018-08-815951 · Cited by 136
Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies
Saliba, J., Saint‐Martin, C., Stefano, A. D., Lenglet, G., Marty, C., Keren, B., Pasquier, F., Della-Valle, V., Secardin, L., Leroy, G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3380 · Cited by 148
Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia
Hirsch, P., Zhang, Y., Tang, R., Joulin, V., Boutroux, H., Pronier, E., Moatti, H., Flandrin‐Gresta, P., Marzac, C., Bories, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12475 · Cited by 144
Velten, L., Story, B. A., Hernández-Malmierca, P., Raffel, S., Leonce, D. R., Milbank, J. H., Paulsen, M. S., Demir, A., Szu‐Tu, C., Frömel, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21650-1 · Cited by 144
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
Miller, P. G., Sperling, A. S., Brea, E. J., Leick, M. B., Fell, G. G., Jan, M., Gohil, S. H., Tai, Y., Munshi, N. C., Wu, C. J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004554 · Cited by 137
Self-citationSomatic mosaicism: on the road to cancer
Fernández, L. C., Torres, M., & Real, F. X. (2015) · Nature reviews. Cancer · doi:10.1038/nrc.2015.1 · Cited by 137
Girelli, D., Marchi, G., & Camaschella, C. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000040 · Cited by 137
Bacher, U., Shumilov, E., Flach, J., Porret, N. A., Joncourt, R., Wiedemann, G., Fiedler, M., Novak, U., Amstutz, U., & Pabst, T. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0148-6 · Cited by 136
Targeting Cardiac Stem Cell Senescence to Treat Cardiac Aging and Disease
Cianflone, E., Torella, M., Biamonte, F., Angelis, A. D., Urbanek, K., Costanzo, F. S., Rota, M., Ellison, G. M., & Torella, D. (2020) · Cells · doi:10.3390/cells9061558 · Cited by 137
Nangalia, J., Nice, F. L., Wedge, D. C., Godfrey, A. L., Grinfeld, J., Thakker, C. E., Massie, C. E., Baxter, E. J., Sewell, D., Silber, Y., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.129510 · Cited by 139
Kim, T., Tyndel, M. S., Kim, H. J., Ahn, J.-S., Choi, S. H., Park, H. J., Kim, Y.-K., Kim, S. Y., Lipton, J. H., Zhang, Z., et al. (2017) · Blood · doi:10.1182/blood-2016-04-708560 · Cited by 133
Unnikrishnan, A., Papaemmanuil, E., Beck, D., Deshpande, N., Verma, A., Kumari, A., Woll, P. S., Richards, L. A., Knezevic, K., Chandrakanthan, V., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.067 · Cited by 137
The interplay of leukemia cells and the bone marrow microenvironment
Duarte, D., Hawkins, E. D., & Celso, C. L. (2018) · Blood · doi:10.1182/blood-2017-12-784132 · Cited by 135
Clonal hematopoiesis associated with epigenetic aging and clinical outcomes
Nachun, D. C., Lu, A. T.-H., Bick, A. G., Natarajan, P., Weinstock, J. S., Szeto, M. D., Kathiresan, S., Abecasis, G. R., Taylor, K. D., Guo, X., et al. (2021) · Aging Cell · doi:10.1111/acel.13366 · Cited by 136
Self-citationLongitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects
Robertson, N. A., Latorre-Crespo, E., Terradas-Terradas, M., Lemos-Portela, J., Purcell, A. C., Livesey, B. J., Hillary, R. F., Murphy, L., Fawkes, A., MacGillivray, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01883-3 · Cited by 132
Clonal Hematopoiesis: Mechanisms Driving Dominance of Stem Cell Clones
Challen, G., & Goodell, M. A. (2020) · Blood · doi:10.1182/blood.2020006510 · Cited by 131
Somatic TP53 variants frequently confound germ-line testing results
Weitzel, J. N., Chao, E., Nehoray, B., Tongeren, L. R. V., LaDuca, H., Blazer, K. R., Slavin, T. P., Pesaran, T. F., Rybak, C., Solomon, I. B., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.196 · Cited by 132
Cancer spectrum and outcomes in the Mendelian short telomere syndromes
Schratz, K. E., Haley, L. M., Danoff, S. K., Blackford, A. L., Dezern, A. E., Gocke, C. D., Duffield, A. S., & Armanios, M. Y. (2020) · Blood · doi:10.1182/blood.2019003264 · Cited by 131
Pathophysiology of Acute Myeloid Leukemia
Wachter, F., & Pikman, Y. (2024) · Acta Haematologica · doi:10.1159/000536152 · Cited by 140
Jakobsen, N. A., Turkalj, S., Zeng, A. G. X., Stoilova, B., Metzner, M., Rahmig, S., Nagree, M. S., Shah, S., Moore, R., Usukhbayar, B., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.05.010 · Cited by 130
Felix, A. S., Bower, J. K., Pfeiffer, R. M., Raman, S. V., Cohn, D. E., & Sherman, M. E. (2016) · International Journal of Cancer · doi:10.1002/ijc.30470 · Cited by 130
Precancer Atlas to Drive Precision Prevention Trials
Spira, A. E., Yurgelun, M. B. B., Alexandrov, L. B., Rao, A., Bejar, R., Polyák, K., Giannakis, M., Shilatifard, A., Finn, O. J., Dhodapkar, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2346 · Cited by 134
Granulopoiesis and Neutrophil Homeostasis: A Metabolic, Daily Balancing Act
Yvan‐Charvet, L., & Ng, L. G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.05.004 · Cited by 137
Alborelli, I., Generali, D., Jermann, P. M., Cappelletti, M. R., Ferrero, G., Scaggiante, B., Bortul, M., Zanconati, F., Nicolet, S., Haegele, J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1770-3 · Cited by 133
Clonal hematopoiesis: Mutation-specific adaptation to environmental change
Florez, M. A., Tran, B. T., Wathan, T. K., DeGregori, J., Pietras, E. M., & King, K. Y. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.05.006 · Cited by 129
Extracellular serine controls epidermal stem cell fate and tumour initiation
Baksh, S. C., Todorova, P. K., Gur-Cohen, S., Hurwitz, B., Ge, Y., Novak, J. S. S., Tierney, M. T., dela Cruz-Racelis, J., Fuchs, E., & Finley, L. W. S. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0525-9 · Cited by 128
Mossner, M., Jann, J.-C., Wittig, J., Nolte, F., Fey, S., Nowak, V., Obländer, J., Pressler, J., Palme, I., Xanthopoulos, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679167 · Cited by 135
Costantino, S., Libby, P., Kishore, R., Tardif, J., El‐Osta, A., & Paneni, F. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx568 · Cited by 128
Coombs, C. C., Gillis, N., Tan, X. M., Berg, J. S., Ball, M., Balasis, M. E., Montgomery, N. D., Bolton, K. L., Parker, J. S., Mesa, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1201 · Cited by 130
Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
Asada, S., Goyama, S., Inoue, D., Shikata, S., Takeda, R., Fukushima, T., Yonezawa, T., Fujino, T., Hayashi, Y., Kawabata, K. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05085-9 · Cited by 132
Barbui, T., Thiele, J., Vannucchi, A. M., & Tefferi, A. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.64 · Cited by 128
Wang, S. A., Tam, W., Tsai, A. G., Arber, D. A., Hasserjian, R. P., Geyer, J. T., George, T. I., Czuchlewski, D. R., Foucar, K. K., Rogers, H. J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.75 · Cited by 126
Ferrando, A. A., & López-Otín, C. (2017) · Nature Medicine · doi:10.1038/nm.4410 · Cited by 132
Hellmann, M. D., Nabet, B. Y., Rizvi, H. A., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P., Chabon, J. J., Liu, C. L., Hui, A. B., Arbour, K. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3418 · Cited by 128
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer
Karlstaedt, A., Moslehi, J. J., & de Boer, R. A. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00698-6 · Cited by 130
Hackl, H., Astanina, K., & Wieser, R. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0416-0 · Cited by 130
Somatic mutations and clonal hematopoiesis in congenital neutropenia
Xia, J., Miller, C. A., Baty, J., Ramesh, A., Jotte, M. R. M., Fulton, R. S., Vogel, T. P., Cooper, M. A., Walkovich, K. J., Makaryan, V., et al. (2017) · Blood · doi:10.1182/blood-2017-08-801985 · Cited by 128
Macrophages and Cardiovascular Health
Frodermann, V., & Nahrendorf, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00068.2017 · Cited by 128
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Cocciardi, S., Dolnik, A., Kapp‐Schwoerer, S., Rücker, F. G., Lux, S., Blätte, T. J., Skambraks, S., Krönke, J., Heidel, F. H., Schnoeder, T. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09745-2 · Cited by 128
Paradoxical association of TET loss of function with genome-wide DNA hypomethylation
López-Moyado, I. F., Tsagaratou, A., Yuita, H., Seo, H., Delatte, B., Heinz, S., Benner, C. W., & Rao, A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903059116 · Cited by 130
Clonal evolution of acute myeloid leukemia from diagnosis to relapse
Vosberg, S., & Greif, P. A. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22806 · Cited by 135
From DNA damage to mutations: All roads lead to aging
Vijg, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101316 · Cited by 133
Garg, M., Karpiński, M., Matelska, D., Middleton, L., Burren, O. S., Hu, F., Wheeler, E., Smith, K. R., Fabre, M. A., Mitchell, J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01898-1 · Cited by 134
Clinical Implications of Clonal Hematopoiesis
Steensma, D. P. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.002 · Cited by 126
Sanders, M. A., Chew, E., Flensburg, C., Zeilemaker, A., Miller, S. E., Hinai, A. S. A. A., Bajel, A. R., Luiken, B., Rijken, M., McLennan, T. J., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852566 · Cited by 126
Vulnerable Plaque, Characteristics, Detection, and Potential Therapies
Hafiane, A. (2019) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd6030026 · Cited by 130
The Role of Telomeres in Human Disease
Armanios, M. Y. (2022) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-010422-091101 · Cited by 126
Gullotta, G. S., Feo, D. D., Friebel, E., Semerano, A., Scotti, G. M., Bergamaschi, A., Butti, E., Brambilla, E., Genchi, A., Capotondo, A., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01505-1 · Cited by 124
Age-associated changes in human hematopoietic stem cells
Pang, W. W., Schrier, S. L., & Weissman, I. L. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.10.004 · Cited by 126
Prassek, V. V., Rothenberg‐Thurley, M., Sauerland, M. C., Herold, T., Janke, H., Ksienzyk, B., Konstandin, N. P., Görlich, D., Krug, U. O., Faldum, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191536 · Cited by 125
Immunometabolic Crosstalk: An Ancestral Principle of Trained Immunity?
Penkov, S., Mitroulis, I., Hajishengallis, G., & Chavakis, T. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.11.002 · Cited by 128
The Role of IDH Mutations in Acute Myeloid Leukemia
Bravo, G. M., & Dinardo, C. D. (2018) · Future Oncology · doi:10.2217/fon-2017-0523 · Cited by 128
Mupo, A., Seiler, M., Sathiaseelan, V., Pance, A., Yang, Y., Agrawal, A. A., Iorio, F., Bautista, R., Pacharne, S., Tzelepis, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.251 · Cited by 128
Lemonnier, F., Cairns, R. A., Inoue, S., Li, W. Y., Dupuy, A., Broutin, S., Martin, N., Fataccioli, V., Pelletier, R., Wakeham, A. C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617929114 · Cited by 125
Advances in understanding the pathogenesis of acquired aplastic anaemia
Luzzatto, L., & Risitano, A. M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15443 · Cited by 124
Losing Sense of Self and Surroundings: Hematopoietic Stem Cell Aging and Leukemic Transformation
Verovskaya, E. V., Dellorusso, P. V., & Passegue, E. A. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.04.006 · Cited by 130
Hematopoietic stem cells through the ages: A lifetime of adaptation to organismal demands
Kasbekar, M., Mitchell, C. A., Proven, M. A., & Passegue, E. A. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.09.013 · Cited by 130
Takahashi, K., Wang, F., Morita, K., Yan, Y., Hu, P. C., Zhao, P., Zhar, A. A., Wu, C., Gumbs, C. E., Little, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04924-z · Cited by 123
Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway
Chen, S., Wang, Q., Yu, H., Capitano, M. L., Vemula, S., Nabinger, S. C., Gao, R., Yao, C., Kobayashi, M., Geng, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13542-2 · Cited by 126
Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity
Cook, E. K., Luo, M., & Rauh, M. J. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.011 · Cited by 124
Multiparameter prediction of myeloid neoplasia risk
Gu, M., Kovilakam, S. C., Dunn, W. G., Marando, L., Bárcena, C., Mohorianu, I. I., Smith, A. G., Kar, S., Fabre, M. A., Gerstung, M., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01472-1 · Cited by 124
Babushok, D. V., Bessler, M., & Olson, T. S. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1115041 · Cited by 122
RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML
Crews, L. A., Balaian, L., Santos, N. P. D., Leu, H. S., Court, A. C., Lazzari, E., Sadarangani, A., Zipeto, M., Clair, J. J. L., Villa, R., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.08.003 · Cited by 123
Sun, L., & Babushok, D. V. (2020) · Blood · doi:10.1182/blood.2019000940 · Cited by 126
Obesity-induced inflammation exacerbates clonal hematopoiesis
Pasupuleti, S. K., Ramdas, B., Burns, S. S., Palam, L. R., Kanumuri, R., Kumar, R., Pandhiri, T. R., Davé, U. P., Yellapu, N. K., Zhou, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163968 · Cited by 125
Self-citationBone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia
Percival, M. M., Lai, C., Estey, E. H., & Hourigan, C. S. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.01.003 · Cited by 122
Potus, F., Pauciulo, M. W., Cook, E. K., Zhu, N., Hsieh, A., Welch, C. L., Shen, Y., Tian, L., Lima, P., Mewburn, J. D., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044320 · Cited by 124
Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
Hasserjian, R. P., Steensma, D. P., Graubert, T. A., & Ebert, B. L. (2020) · Blood · doi:10.1182/blood.2019004770 · Cited by 118
Self-citationNCCN Guidelines Insights: Survivorship, Version 2.2020
Denlinger, C. S., Sanft, T. B., Moslehi, J. J., Overholser, L., Armenian, S. H., Baker, K. S., Broderick, G. A., Demark‐Wahnefried, W., Friedman, D. L., Goldman, M. E., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0037 · Cited by 120
Clinical Circulating Tumor DNA Testing for Precision Oncology
Kim, H., & Park, K. U. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1026 · Cited by 121
Molecular mechanisms in colitis-associated colorectal cancer
Zhou, R. W., Harpaz, N., Itzkowitz, S. H., & Parsons, R. E. (2023) · Oncogenesis · doi:10.1038/s41389-023-00492-0 · Cited by 123
Clonal hematopoiesis driven by mutated DNMT3A promotes inflammatory bone loss
Wang, H., Divaris, K., Pan, B., Li, X., Lim, J., Saha, G., Barovic, M., Giannakou, D., Korostoff, J. M., Bing, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.003 · Cited by 122
Molecular pathogenesis of the myeloproliferative neoplasms
Greenfield, G., McMullin, M. F., & Mills, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01116-z · Cited by 128
Savola, P., Kelkka, T., Rajala, H. L. M., Kuuliala, A., Kuuliala, K., Eldfors, S., Ellonen, P., Lagström, S., Lepistö, M., Hannunen, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms15869 · Cited by 119
Diverse mutational landscapes in human lymphocytes
Machado, H. E., Mitchell, E., Øbro, N. F., Kübler, K., Davies, M., Leongamornlert, D., Cull, A., Maura, F., Sanders, M. A., Cagan, A. T. J., et al. (2022) · Nature · doi:10.1038/s41586-022-05072-7 · Cited by 116
Self-citationEmergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia
Babushok, D. V., Perdigones, N., Perin, J. C., Olson, T. S., Ye, W., Roth, J. J., Lind, C., Cattier, C., Li, Y., Hartung, H. D., et al. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.01.007 · Cited by 118
Heuser, M., Heida, B., Büttner, K., Wienecke, C. P., Teich, K., Funke, C., Brandes, M., Klement, P., Liebich, A., Wichmann, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004367 · Cited by 119
Metadata
- Authors
- Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., Higgins, J. M., Moltchanov, V., Kuo, F. C., Kluk, M. J., Henderson, B., Kinnunen, L., Koistinen, H. A., Ladenvall, C., Getz, G., Correa, A., Banahan, B. F., Gabriel, S., Kathiresan, S., Stringham, H. M., McCarthy, M. I., Boehnke, M., Tuomilehto, J., Haiman, C., Groop, L., Atzmon, G., Wilson, J. G., Neuberg, D., Altshuler, D., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- University of Helsinki (FI)
- University of Southern California (US)
- Helsinki University Hospital (FI)
- Lund University (SE)
- University of Mississippi Medical Center (US)
- University of Michigan (US)
- Centre for Human Genetics (GB)
- Universität für Weiterbildung Krems (AT)
- Albert Einstein College of Medicine (US)
- Harvard University (US)
- ORCID
- Jaiswal, Siddhartha
- Fontanillas, Pierre
- Flannick, Jason
- Manning, Alisa
- Mar, Brenton G.
- Lindsley, R. Coleman
- Mermel, Craig H.
- Chavez, Alejandro
- Higgins, John M.
- Kuo, Frank C.
- Kluk, Michael J.
- Kinnunen, Leena
- Koistinen, Heikki A.
- Ladenvall, Claes
- Getz, Gad
- Correa, Adolfo
- Banahan, Benjamin F.
- Gabriel, Stacey
- Kathiresan, Sekar
- Stringham, Heather M.
- McCarthy, Mark I.
- Boehnke, Michael
- Tuomilehto, Jaakko
- Groop, Leif
- Atzmon, Gil
- Wilson, James G.
- Neuberg, Donna
- Altshuler, David
- Ebert, Benjamin L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2488-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4306669
- OpenAlex
- W2149858388
- Cited by
- 4,841
- References
- 48
- Citations by year
- 2026: 423 · 2025: 446 · 2024: 494 · 2023: 521 · 2022: 536 · 2021: 520 · 2020: 454 · 2019: 387 · 2018: 356 · 2017: 301 · 2016: 237 · 2015: 151 · 2014: 6
- FWCI
- 164.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Funders
- Wellcome Trust (090367, 085475, 098381, 090532, 083948)
- National Institutes of Health (5rc2dk088389-02)
- National Institute on Aging (R01AG042188, P01AG021654, P30AG038072)
- National Heart, Lung, and Blood Institute (R01HL082945, T32HL066987)
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (T32CA009216, T32CA009172, P01CA066996)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK085526, U01DK085584, DP2DK098087, U01DK085501, U01DK085524, RC2-DK088389, U01DK085545, DK088389, P30DK020572)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- age-related clonal hematopoiesis, somatic mutations, all-cause mortality, coronary artery disease, ischemic stroke, cardiovascular disease, DNMT3A, TET2, ASXL1, peripheral blood, aging
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
